{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T14:20:31Z","timestamp":1775744431800,"version":"3.50.1"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,10,3]]},"DOI":"10.7759\/cureus.18460","type":"journal-article","created":{"date-parts":[[2021,10,4]],"date-time":"2021-10-04T16:44:27Z","timestamp":1633365867000},"source":"Crossref","is-referenced-by-count":7,"title":["Erythrodermic Psoriasis Exacerbated by Bupropion"],"prefix":"10.7759","author":[{"given":"Michael G","family":"Foss","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy","family":"Nyckowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"Steffes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jemermed.2016.11.034","article-title":"Acute generalized erythrodermic pustular psoriasis associated with bupropion\/naltrexone (Contrave\u00ae)","volume":"52","author":"Singh PA","year":"2017","unstructured":"Singh PA, Cassel KP, Moscati RM, Eckersley D. Acute generalized erythrodermic pustular psoriasis associated with bupropion\/naltrexone (Contrave\u00ae). J Emerg Med. 2017, 52:111-3. 10.1016\/j.jemermed.2016.11.034","journal-title":"J Emerg Med"},{"key":"ref2","article-title":"Psoriasis","author":"van de Kerkhof PC","year":"2017","unstructured":"van de Kerkhof PC, Nestl\u00e9 FO. Psoriasis. Dermatology. Bolognia J, Schaffer J, Cerroni L (ed): Elsevier, Philadelphia, PA; 2017. 4th ed.:138-60."},{"key":"ref3","article-title":"Erythroderma","author":"Whittaker S","year":"2017","unstructured":"Whittaker S. Erythroderma. Dermatology. Bolognia J, Schaffer J, Cerroni L (ed): Elsevier, Philadelphia, PA; 2017. 4th ed.:175-87."},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2009.05.048","article-title":"Treatment of erythrodermic psoriasis: from the medical board of the National Psoriasis Foundation","volume":"62","author":"Rosenbach M","year":"2010","unstructured":"Rosenbach M, Hsu S, Korman NJ, Lebwohl MG, Young M, Bebo BF Jr, Van Voorhees AS. Treatment of erythrodermic psoriasis: from the medical board of the National Psoriasis Foundation. J Am Acad Dermatol. 2010, 62:655-62. 10.1016\/j.jaad.2009.05.048","journal-title":"J Am Acad Dermatol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/s0190-9622(96)90078-x","article-title":"Infectious complications of erythrodermic psoriasis","volume":"34","author":"Green MS","year":"1996","unstructured":"Green MS, Prystowsky JH, Cohen SR, Cohen JI, Lebwohl MG. Infectious complications of erythrodermic psoriasis. J Am Acad Dermatol. 1996, 34:911-4. 10.1016\/s0190-9622(96)90078-x","journal-title":"J Am Acad Dermatol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.03.073","article-title":"Treatment of erythrodermic psoriasis with biologics: a systematic review","volume":"83","author":"Carrasquillo OY","year":"2020","unstructured":"Carrasquillo OY, Pab\u00f3n-Cartagena G, Falto-Aizpurua LA, Santiago-V\u00e1zquez M, Cancel-Artau KJ, Arias-Berrios G, Mart\u00edn-Garc\u00eda RF. Treatment of erythrodermic psoriasis with biologics: a systematic review. J Am Acad Dermatol. 2020, 83:151-8. 10.1016\/j.jaad.2020.03.073","journal-title":"J Am Acad Dermatol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.2002.04679.x","article-title":"Generalized pustular and erythrodermic psoriasis associated with bupropion treatment","volume":"146","author":"Cox NH","year":"2002","unstructured":"Cox NH, Gordon PM, Dodd H. Generalized pustular and erythrodermic psoriasis associated with bupropion treatment. Br J Dermatol. 2002, 146:1061-3. 10.1046\/j.1365-2133.2002.04679.x","journal-title":"Br J Dermatol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.13876","article-title":"Erythrodermic psoriasis induced by bupropion","volume":"31","author":"Matos-Pires E","year":"2017","unstructured":"Matos-Pires E, Campos S, Mendes-Bastos P, Jo\u00e3o A, Fernandes C. Erythrodermic psoriasis induced by bupropion. J Eur Acad Dermatol Venereol. 2017, 31:129-30. 10.1111\/jdv.13876","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref9","article-title":"A case of bupropion-induced Stevens-Johnson syndrome with acute psoriatic exacerbation","volume":"9","author":"Surovik J","year":"2010","unstructured":"Surovik J, Riddel C, Chon SY. A case of bupropion-induced Stevens-Johnson syndrome with acute psoriatic exacerbation. J Drugs Dermatol. 2010, 9:1010-2.","journal-title":"J Drugs Dermatol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1684\/ejd.2010.1180","article-title":"Drug eruption and exacerbation of psoriasis related to bupropion","volume":"21","author":"G\u00f3mez-Fern\u00e1ndez C","year":"2011","unstructured":"G\u00f3mez-Fern\u00e1ndez C, Herranz Pinto P, Casado Verrier B, Sendagorta Cud\u00f3s E, Beato-Merino MJ, Jim\u00e9nez MC. Drug eruption and exacerbation of psoriasis related to bupropion. Eur J Dermatol. 2011, 21:120-1. 10.1684\/ejd.2010.1180","journal-title":"Eur J Dermatol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1177\/2045125316629071","article-title":"Bupropion: a systematic review and meta-analysis of effectiveness as an antidepressant","volume":"6","author":"Patel K","year":"2016","unstructured":"Patel K, Allen S, Haque MN, Angelescu I, Baumeister D, Tracy DK. Bupropion: a systematic review and meta-analysis of effectiveness as an antidepressant. Ther Adv Psychopharmacol. 2016, 6:99-144. 10.1177\/2045125316629071","journal-title":"Ther Adv Psychopharmacol"},{"key":"ref12","unstructured":"Wellbutrin\u00ae (bupropion hydrochloride) tablets. Accessed. August 11, 2021: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/018644s043lbl.pdf."},{"key":"ref13","unstructured":"Zyban\u00ae (bupropion hydrochloride) sustained-release tablets. (2011). Accessed. August 11, 2021: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/020711s026lbl.pdf."},{"key":"ref14","unstructured":"Contrave\u00ae (naltrexone HCl and bupropion HCl) extended release tablets. (2014). Accessed. August 11, 2021: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/200063s000lbl.pdf."},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200831110-00006","article-title":"Serious adverse reactions of bupropion for smoking cessation: analysis of the French Pharmacovigilance Database from 2001 to 2004","volume":"31","author":"Beyens MN","year":"2008","unstructured":"Beyens MN, Guy C, Mounier G, Laporte S, Ollagnier M. Serious adverse reactions of bupropion for smoking cessation: analysis of the French Pharmacovigilance Database from 2001 to 2004. Drug Saf. 2008, 31:1017-26. 10.2165\/00002018-200831110-00006","journal-title":"Drug Saf"},{"key":"ref16","unstructured":"Package leaflet. Information for the user: Zyban\u00ae. (2021). Accessed: August 11, 2021: https:\/\/www.medicines.org.uk\/emc\/files\/pil.3827.pdf."},{"key":"ref17","article-title":"Psoriasis: classical and emerging comorbidities","volume":"90","author":"De Oliveira M","year":"2015","unstructured":"De Oliveira M, de Oliveira Rocha B, Duarte GV. Psoriasis: classical and emerging comorbidities. An Bras Dermatol. 2015, 90:9-20.","journal-title":"An Bras Dermatol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.07.064","article-title":"Psoriasis and comorbid diseases: epidemiology","volume":"76","author":"Takeshita J","year":"2017","unstructured":"Takeshita J, Grewal S, Langan SM, Mehta NN, Ogdie A, Van Voorhees AS, Gelfand JM. Psoriasis and comorbid diseases: epidemiology. J Am Acad Dermatol. 2017, 76:377-90. 10.1016\/j.jaad.2016.07.064","journal-title":"J Am Acad Dermatol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.14460","article-title":"Depression and suicidality in psoriasis: review of the literature including the cytokine theory of depression","volume":"31","author":"Koo J","year":"2017","unstructured":"Koo J, Marangell LB, Nakamura M, Armstrong A, Jeon C, Bhutani T, Wu JJ. Depression and suicidality in psoriasis: review of the literature including the cytokine theory of depression. J Eur Acad Dermatol Venereol. 2017, 31:1999-2009. 10.1111\/jdv.14460","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01507","article-title":"An update on the role of adipose tissues in psoriasis","volume":"10","author":"Wong Y","year":"2019","unstructured":"Wong Y, Nakamizo S, Tan KJ, Kabashima K. An update on the role of adipose tissues in psoriasis. Front Immunol. 2019, 10:10.3389\/fimmu.2019.01507","journal-title":"Front Immunol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/72476-erythrodermic-psoriasis-exacerbated-by-bupropion","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:30:33Z","timestamp":1707507033000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/72476-erythrodermic-psoriasis-exacerbated-by-bupropion"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,3]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.18460","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10,3]]}}}